Israel Englander Exagen Inc. Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Exagen Inc. stock. As of the latest transaction made, Millennium Management LLC holds 23,860 shares of XGN stock, worth $43,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,860

Previous 23,615 1.04%

Holding current value

$43,425

Previous $46,000 19.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.42 - $2.3 $347 - $563	245 Added 1.04%	23,860 $37,000
Q4 2023 Feb 14, 2024	SELL	$1.45 - $2.39 $9,265 - $15,272	-6,390 Reduced 21.3%	23,615 $46,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.48 $7,434 - $10,962	-3,150 Reduced 9.5%	30,005 $87,000
Q1 2023 May 15, 2023	SELL	$2.23 - $2.9 $7,653 - $9,952	-3,432 Reduced 9.38%	33,155 $81,000
Q4 2022 Feb 14, 2023	SELL	$2.1 - $3.4 $27,134 - $43,931	-12,921 Reduced 26.1%	36,587 $88,000

Q3 2022 Nov 14, 2022	SELL	$3.43 - $8.68 $103,315 - $261,450	-30,121 Reduced 37.83%	49,508 $134,000
Q2 2022 Aug 15, 2022	BUY	$4.18 - $7.74 $332,849 - $616,328	79,629 New	79,629 $457,000
Q1 2022 May 16, 2022	SELL	$7.12 - $11.06 $208,573 - $323,991	-29,294 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$8.97 - $14.08 $50,743 - $79,650	-5,657 Reduced 16.19%	29,294 $341,000
Q3 2021 Nov 15, 2021	SELL	$10.25 - $15.21 $421,346 - $625,237	-41,107 Reduced 54.05%	34,951 $475,000
Q2 2021 Aug 16, 2021	BUY	$12.4 - $17.92 $943,119 - $1.36 Million	76,058 New	76,058 $1.14 Million
Q4 2019 Feb 14, 2020	SELL	$12.61 - $28.48 $478,726 - $1.08 Million	-37,964 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$14.5 - $17.5 $550,478 - $664,370	37,964 New	37,964 $588,000

Others Institutions Holding XGN

# of Institutions

Shares Held

6.21M

Call Options Held

1.6K

Put Options Held

4.1K

View Full List

About EXAGEN INC.

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $29.6M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

More about XGN

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account